The mammalian target of rapamycin (mTOR) controls lipid biosynthesis via various effector molecules, such as sterol regulatory element-binding protein like-1c (SREBP-1c) [3] which engages in the development of hepatic steatosis [4]. This evidence concerns the gene MTOR and fatty liver disease.